国际肿瘤学杂志

国际肿瘤学杂志 ›› 2013, Vol. 40 ›› Issue (8): 598-600.

• 综述 • 上一篇    下一篇

晚期非小细胞肺癌厄洛替尼耐药研究进展

于学娟, 张品良, 任瑞美   

  1. 250117济南，山东省肿瘤医院内六科；济南大学 山东省医学科学院医学与生命科学学院

  • 出版日期:2013-08-08 发布日期:2013-08-15
  • 通讯作者: 任瑞美，E-mail:ruimeiren@sina.com E-mail:ruimeiren@sina.com

Drug resistance of advanced non-small cell lung cancer treated by erlotinib

YU  Xue-Juan, ZHANG  Pin-Liang, REN  Rui-Mei   

  1. The Sixth Department of Oncology， Shandong Cancer Hospital, Shandong Academy of Medical Sciences, University of Jinan-Shandong, Jinan 250117, China

  • Online:2013-08-08 Published:2013-08-15
  • Contact: Corresponding author：REN Rui-mei, E-mail: ruimeiren@sina.com E-mail:ruimeiren@sina.com

PDF

1592

被引次数

4

摘要： 酪氨酸激酶抑制剂（TKI）厄洛替尼作为晚期非小细胞肺癌（NSCLC）靶向治疗药物，延长了患者的生存时间，但其耐药性的发生成为其进一步应用的瓶颈。现已证实T790M突变、KRAS突变、c-met癌基因扩增在耐药机制中起重要作用。针对不同耐药机制，第2代TKI的应用、再次应用化疗或厄洛替尼以及针对失败模式进行后续治疗等多项临床试验不断开展。

关键词: 癌, 非小细胞肺, 抗药性, 肿瘤, 抗肿瘤药

Abstract: Erlotinib, a kind of epidermal growth factor receptor tyrosine kinase inhibitors ( EGFR-TKIs), has been effectively used in the treatment of non-small cell lung cancer (NSCLC). Although it prolongs patients survival time, erlotinib is limited to be further applied for its resistance. It has been proved that threonine to  methionine mutations in codon 790 (T790M), Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation and the amplification of met oncogene play important roles in the drug resistance. Based on the different molecular mechanisms of resistance, multiple clinical trials of the second generation TKIs, retreatment of chemotherapy or erlotinib and subsequent treatment according to failure modes have been developed.

Key words: Carcinoma, non-small-cell lung, Drug resistance, neoplasm, Antineoplastic agents